Etoposide
Top View
- A Randomised Trial of Three Or Six Courses of Etoposide Cyclophosphamide
- Arsenic Trioxide Sensitivity Is Associated with Low Level Of
- Therapeutic Drug Monitoring of 21-Day Oral Etoposide in Patients with Advanced Non-Small Cell Lung Cancer’
- Targeting the Human 80S Ribosome in Cancer: from Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies
- Induction of Sensitivity to Doxorubicin and Etoposide by Transfection of MCF-7 Breast Cancer Cells with Heregulin F3-2’
- High Dose Melphalan, BCNU and Etoposide with Autologous Bone Marrow Transplantation for Hodgkin's Disease
- Etoposide Products
- Teniposide Injection
- LUNG CANCER TREATMENT REGIMENS (Part 1 of 7) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Handling Cytostatic Drugs: Contents
- VUMON® (Teniposide Injection)
- The Combination of Reduced MCL-1 and Standard Chemotherapeutics Is Tolerable in Mice
- RCEOP-Cyclophosphamide-Etoposide-Prednisolone-Rituximab-Vincristine Ver
- Subcutaneous Omacetaxine Mepesuccinate in Patients With
- Superiority of Sequential Versus Concurrent Administration of Paclitaxel with Etoposide in Advanced Non-Small Cell Lung Cancer: Comparison of Two Phase II Trials’
- Hydroxycarbamide for Acute Myeloid Leukaemia (AML)
- Arsenic Trioxide Utilization Review Medical Policy • Arsenic Trioxide Injection for Intravenous Use (Trisenox® – Teva Pharmaceuticals, Generics)